The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation.
about
Gonadotrophin-releasing hormone antagonists for assisted reproductive technologyGonadotrophin-releasing hormone antagonists for assisted reproductive technologyObesity is not associated with the poor pregnancy outcome following intracytoplasmic sperm injection in women with polycystic ovary syndrome.Individualized Treatment from Theory to Practice: The Private Case of Adding LH during GnRH Antagonist-based Stimulation Protocol.Gonadotrophins: The future.Impact of exogenous gonadotropin stimulation on circulatory and follicular fluid cytokine profilesClinical effects of a natural extract of urinary human menopausal gonadotrophin in normogonadotropic infertile patientsThe role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment?Treatment of female infertility with recombinant human luteinising hormone: is there a benefit over other available drugs?Exogenous hCG activity, but not endogenous LH activity, is positively associated with live birth rates in anovulatory infertility.Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: a meta-analysis.Early initiation of gonadotropin-releasing hormone antagonist in polycystic ovarian syndrome patients undergoing assisted reproduction: randomized controlled trial ISRCTN69937179.Live-birth rates after HP-hMG stimulation in the long GnRH agonist protocol: association with mid-follicular hCG and progesterone concentrations, but not with LH concentrations.Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study.Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review.Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation.Controlled ovarian hyperstimulation regimens: a review of the available evidence for clinical practice. Produced on behalf of the BFS Policy and Practice Committee.Clomiphene citrate is associated with favorable cycle characteristics but impaired outcomes of obese women with polycystic ovarian syndrome undergoing ovarian stimulation for in vitro fertilization.Does day-3 LH/FSH ratio influence in vitro fertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue?LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels.A novel modified ultra-long agonist protocol improves the outcome of high body mass index women with polycystic ovary syndrome undergoing IVF/ICSI.Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy.Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation.Combination of recombinant follicle stimulating hormone with human menopausal gonadotrophin or recombinant luteinizing hormone in a long gonadotrophin-releasing hormone agonist protocol: a retrospective study.
P2860
Q24185849-8E985A45-9C1A-4B93-974C-8DA6E0A14C05Q24234608-4E13CCBF-56E6-4EA5-BDB8-54E7A108720DQ34330406-AF3BF468-85AA-4468-8C2F-53D4016DA54FQ34421570-1C6785F5-4394-48C8-9F6D-4B9651D43187Q34975528-DE6274F9-01B9-43F7-BC60-353F25682260Q35100094-C0262449-5271-49D0-8147-2F3FD8B23143Q35178167-13858831-2BF5-4B82-88C3-9913C2D935DCQ35206247-4397B1B3-0B1F-4E88-83C1-660D199DD31BQ35574981-FDEE91F4-D574-4BF8-9A54-8AB1D2D3C490Q35650609-F88B3B05-9430-472C-8D39-8D9D32430BA3Q36268571-460AF27D-627A-40B4-A19B-A595DDE3E20AQ36434675-5B38A0A5-E655-44EC-9909-F025EF573D65Q36456037-614A39CB-9881-4BF3-8E0B-24364DE005C9Q37240215-17475C41-AD59-4C13-9DC2-6C86780D63F6Q37303241-A81D6700-3030-495A-8857-FECD6A16FAC9Q37658028-F132430E-0B23-4BEA-A6A4-45E5F1B17A3BQ38109225-84B116BD-4C07-437C-BC16-E1F174B4E776Q41390120-0DBD27B2-4129-4E53-8457-6DC41CF8FF68Q42506190-F9B4928D-E5B0-42B4-84B6-294EAC2EFBF8Q43283454-FFACEEF0-CC73-41A2-9DDD-41ADDE506C10Q44210590-61515324-5FE7-4B99-B172-64809C28FC7DQ45165261-E3C5D825-691C-4DD8-8A02-D691E2E8C577Q47712548-DA329068-28AE-4493-B66E-E8581CD65477Q53070911-CAECAE0B-4FEF-4018-8336-63A23720B5DB
P2860
The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The clinical therapeutic windo ...... ontrolled ovarian stimulation.
@ast
The clinical therapeutic windo ...... ontrolled ovarian stimulation.
@en
The clinical therapeutic windo ...... ontrolled ovarian stimulation.
@nl
type
label
The clinical therapeutic windo ...... ontrolled ovarian stimulation.
@ast
The clinical therapeutic windo ...... ontrolled ovarian stimulation.
@en
The clinical therapeutic windo ...... ontrolled ovarian stimulation.
@nl
prefLabel
The clinical therapeutic windo ...... ontrolled ovarian stimulation.
@ast
The clinical therapeutic windo ...... ontrolled ovarian stimulation.
@en
The clinical therapeutic windo ...... ontrolled ovarian stimulation.
@nl
P1476
The clinical therapeutic windo ...... ontrolled ovarian stimulation.
@en
P2093
Zeev Shoham
P304
P356
10.1016/S0015-0282(02)03157-6
P407
P577
2002-06-01T00:00:00Z